Business
MediWound’s EscharEx Featured in Paper as a Potential Paradigm Shift Towards Non-Surgical Wound Bed Preparation in DFUs
Paper published in the November 2022 issue of Podiatry Management(Robert J. Snyder, DPM, Cyaandi Dove, DPM, and Vickie Driver, DPM, MS) YAVNE, Israel, Nov.
About this update from Mediwound Ltd.
[{"type":"text","content":"Paper published in the November 2022 issue of Podiatry Management(Robert J. Snyder, DPM, Cyaandi Dove, DPM, and Vickie Driver, DPM, MS) YAVNE, Israel, Nov. 09, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the publication of a paper, “Introducing Bromelain-Based Enzymatic Debridement” in the journal Podiatry Management. The paper reviewed past studies and summarized physicians’ experiences in using EscharEx® for the debridement and wound bed preparation of Diabetic Foot Ulcers (DFUs). EscharEx, MediWound’s next generation topical debridement agent is a complex mixture of proteolytic enzymes enriched in bromelain developed for the treatment of chronic and other hard-to-heal wounds. Findings in the paper show EscharEx to be safe and effective, with over 50% of the patients achieving complete debridement within a week, and leaving the wounds with healthy granulation tissue. EscharEx was shown to be significantly more effective than the hydrogel control treatment. Similar results were found in the debridement of Venous Leg Ulcers (VLUs). This represents a potential paradigm shift from surgical debridement to a fast, effective, safe, practical and user-friendly treatment of chronic and hard to heal wounds. “We were pleased to see that the physicians’ experiences highlighted in this paper are similar to the results in our other EscharEx clinical trials,” said Dr. Rob Snyder, Chief Medical Director of EscharEx. “We believe EscharEx, with its compelling efficacy and safety profile to date, has the potential to meaningfully impact the management and care of chronic wounds while offering significant benefits for patients and healthcare professionals. We look forward to its continued development.” DFUs are open sores or wounds that if not properly treated could become infected and require hospitalization. They are likely to affect and endanger up to 34% of diabetic patients at some stage in their lives. Early and effective debridement of the devitalized tissue is a cornerstone for wound healing and even patient survival. The current standard of care is based on two alternative debridement strategies: sharp (surgical) debridement or autolytic/enzymatic (non-surgical) debridement. Shar...